Trial · NCT02545907
Results by group41
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 41
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities as Assessed by Reported Data | Dose Level 0 | 0 | Participants | ||
| Number of Participants With Dose-Limiting Toxicities as Assessed by Reported Data | Dose Level 1 | 1 | Participants | ||
| Number of Participants Experiencing Grade 3 or 4 Toxicity as Assessed by CTCAE v4.0. | Dose Level 0- Safety Population | 2 | Participants | ||
| Number of Participants Experiencing Grade 3 or 4 Toxicity as Assessed by CTCAE v4.0. | Dose Level 1- Safety Population | 3 | Participants | ||
| Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Dose Level 0- Safety Population | Within 3 cycles | 1 | Participants | |
| Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Dose Level 1- Safety Population | Within 3 cycles | 5 | Participants | |
| Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Dose Level 0- Safety Population | At the end of cycle 3 | 1 | Participants | |
| Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Dose Level 1- Safety Population | At the end of cycle 3 | 5 | Participants | |
| Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Dose Level 0- Safety Population | Within 6 cycles | 2 | Participants | |
| Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Dose Level 1- Safety Population | Within 6 cycles | 5 | Participants | |
| Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Dose Level 0- Safety Population | At the end of cycle 6 | 2 | Participants | |
| Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Dose Level 1- Safety Population | At the end of cycle 6 | 5 | Participants | |
| Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment. | Dose Level 0- Safety Population | Response within 3 months | 0 | Participants | |
| Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment. | Dose Level 1- Safety Population | Response within 3 months | 0 | Participants | |
| Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment. | Dose Level 0- Safety Population | Response within 6 months | 0 | Participants | |
| Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment. | Dose Level 1- Safety Population | Response within 6 months | 0 | Participants | |
| Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment. | Dose Level 0- Safety Population | No response | 3 | Participants | |
| Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment. | Dose Level 1- Safety Population | No response | 7 | Participants | |
| Time to Amyloidotic Organ Response Based on Reported Data. | Dose Level 0- Safety Population | 0 | Participants | ||
| Time to Amyloidotic Organ Response Based on Reported Data. | Dose Level 1- Safety Population | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02545907/results